{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 148,
  "pageCount": 415,
  "prevPage": 147,
  "nextPage": 149,
  "slideType": "appendix_data",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a table to map shared mechanisms of edema between GH and Diazoxide, and a second table to highlight the high prevalence of GH use in the P3 study.",
  "elementsJson": [
    "headline_text",
    "comparison_table",
    "paragraph",
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/148",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-148",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "GH + DCCR synergy to drive edema never discussed by Solano. GH also synergistically promotes glycemic dysregulation.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a2-890272f6b17d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Growth Hormone usage rate: 82.4%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a2-8ed5d32c069c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.62
      },
      "kind": "paragraph",
      "text": "DCCR + GH = synergistically increase water retention. Combination therapy potentiates both edema risk and T2D risk. 83% of PWS patients receive GH therapy. GH + DCCR synergy to drive edema never discussed by Solano.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90c17e13-601d-4365-b503-e10a5c64cf6c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.6,
        "x": 0.07,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital analysis and estimates; https://pmc.ncbi.nlm.nih.gov/articles/PMC12181816/pdf/nihms-2090141.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a4ee60b-0fc3-4b9d-bb0b-0b1d13db9aa1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.35,
        "x": 0.07,
        "y": 0.79
      },
      "kind": "table",
      "text": "ITT Population (N=125) table",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7605fb7d-1209-4ac0-945d-c64c5bf81537",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.86,
        "x": 0.07,
        "y": 0.29
      },
      "kind": "table",
      "text": "Shared Mechanisms: Overlapping Pathways to Edema",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "897e4553-0120-44b6-837a-ba8a026140e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Vykat in conjunction with growth hormone - used by most PWS patients - synergistically increases the risk of edema. The P3 open-label extension paper indicates 82.4% of study participant were on growth hormone.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6cf34ac-9e71-4c13-a9a7-f5ca5e17db9c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.07,
        "y": 0.75
      },
      "kind": "title",
      "text": "Phase 3 open-label extension study (C602) – 82% on growth hormone",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a6fce47-b114-4b2c-9416-06f2fcebcdfd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "41868156-0980-4862-87c1-20d5089bec24",
      "evidence": "The slide explicitly accuses the company (Solano) of avoiding disclosure of compounded risks.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}